A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation

William D Chey, Michael Camilleri, Lin Chang, Leif Rikner, Hans Graffner, William D Chey, Michael Camilleri, Lin Chang, Leif Rikner, Hans Graffner

Abstract

Objectives: A3309 is a minimally absorbed ileal bile acid (BA) transporter (IBAT) inhibitor. We conducted an 8-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, phase IIb study, which evaluated A3309 in patients with chronic idiopathic constipation (CIC).

Methods: Patients with CIC (modified Rome III criteria and <3 complete (CSBM) spontaneous bowel movements (SBMs)/week during the 2-week baseline) were randomized to 5, 10, or 15 mg A3309 or placebo once daily. The primary end point was change in SBM number during week 1 compared with baseline. Other bowel and abdominal symptoms were assessed as secondary end points. Serum 7αC4 and lipids were evaluated as biomarkers of BA synthesis/loss.

Results: In all, 190 patients (mean 48 years, 90% female) were randomized. Mean increase (95% confidence interval) in SBM for week 1 were 1.7 (0.7-2.8) for placebo vs. 2.5 (1.5-3.5), 4.0 (2.9-5.0), and 5.4 (4.4-6.4) for 5 mg, 10 mg (P<0.002), and 15 mg (P<0.001) A3309, respectively. Increased stool frequency was maintained over 8 weeks. Time to first SBM and CSBM were significantly reduced in the 10- and 15-mg A3309 groups compared with placebo. Straining and bloating decreased with A3309 compared with placebo (P<0.05). Increased 7αC4 and reduced low-density lipoprotein cholesterol with A3309 suggested increased BA synthesis and BA loss. The most common adverse events (AEs) were abdominal pain and diarrhea, which occurred most commonly in the 15-mg A3309 group. No drug-related serious AEs were observed.

Conclusions: A3309 increased stool frequency and improved constipation-related symptoms in CIC; effects were maintained over 8 weeks of treatment.

Figures

Figure 1
Figure 1
Patient flow diagram. Completer PP (per protocol) population=all intention to treat (ITT) patients who completed the study and were at least 80% compliant with study medication and patient reports during the treatment period. AE, adverse event.
Figure 2
Figure 2
Change from baseline in weekly spontaneous bowel movement (SBM) frequency for treatment week 1. ITT, intention to treat.
Figure 3
Figure 3
Effect of A3309 and placebo on weekly stool frequency. Mean weekly SBM (a) and CSBM (b) frequency. Significance values shown are for the overall change from baseline between A3309 and placebo. ***P<0.001, *P<0.05. CSBM, complete spontaneous bowel movement; ITT, intention to treat; SBM, spontaneous bowel movement.
Figure 4
Figure 4
Effect of A3309 and placebo on weekly stool consistency, straining, and bloating. Changes in stool consistency (a), straining (b), and bloating (c) over the treatment period. Significance values shown are for the overall change from baseline between A3309 and placebo. ***P<0.001, *P<0.05. BSFS, Bristol Stool Form Scale (7-graded scale, see text for explanations); ITT, intention to treat.

References

    1. Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil. 2008;20 (Suppl 1:121–129.
    1. Higgins PD, Johansen JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99:750–759.
    1. Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol. 2001;96:3130–3137.
    1. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25:599–608.
    1. Hofmann AF, Poley JR. Cholestyramine treatment of diarrhea associated with ileal resection. N Engl J Med. 1969;281:397–402.
    1. Hofmann AF, Loening-Baucke V, Lavine JE, et al. Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. J Pediatr Gastroenterol Nutr. 2008;47:598–606.
    1. Abrahamsson H, Ostlund-Lindqvist AM, Nilsson R, et al. Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation. Scand J Gastroenterol. 2008;43:1483–1488.
    1. Rao AS, Wong B, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010;139:1549–1558.
    1. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010;8:159–165.
    1. Bajor A, Gillberg P-G, Abrahamsson H. Bile acids: short and long term effects in the intestine. Scand J Gastroenterol. 2010;45:645–664.
    1. Kirwan WO, Smith AN, Mitchell WD, et al. Bile acids and colonic motility in the rabbit and the human. Gut. 1975;16:894–902.
    1. Conley DR, Coyne MJ, Bonorris GG, et al. Bile acid stimulation of colonic adenylate cyclase and secretion in the rabbit. Am J Dig Dis. 1976;21:453–458.
    1. Chadwick VS, Gaginella TS, Carlson GL, et al. Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. J Lab Clin Med. 1979;94:661–674.
    1. Alrefai WA, Saksena S, Tyagi S, et al. Taurodeoxycholate modulates apical Cl−/OH− exchange activity in Caco2 cells. Dig Dis Sci. 2007;52:1270–1278.
    1. Gillberg PG, Dahlström M, Starke I, et al. The IBAT inhibition by A3309—a potential mechanism for the treatment of constipation. Gastroenterology. 2010;5 (Suppl 1:224.
    1. Simren M, Abrahamsson H, Bajor A, et al. The IBAT inhibitor A3309—a promising treatment option for patients with chronic idiopathic constipation. Gastroenterology. 2010;5 (Suppl 1:223.
    1. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.
    1. O'Donell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. Br Med J. 1990;300:439–440.
    1. Rex D, Johnson DA, Anderson JC, et al. American college of gastroenterology guidelines for colorectal cancer screening 2008. Am J Gastroenterol. 2009;104:739–750.
    1. Food and Drug Administration [Internet] Guidance for Industry: Irritable Bowel Syndrome — Clinical Evaluation of Products for Treatment [updated 4 March 2010; cited 27 January 2011]Available at: : .
    1. Gälman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology. 2005;129:1445–1453.
    1. Angelin B, Eriksson M, Rudling M. Bile acids and lipoprotein metabolism: a renaissance for bile acids in the post-statin era. Curr Opin Lipidol. 1999;10:269–274.
    1. Bertolotti M, Zambianchi L, Carulli L, et al. Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption. Hepatology. 2003;38:939–946.
    1. Naoumova RP, O'Neill FH, Dunn S, et al. Effect of inhibiting HMG-CoA reductase on 7α-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. Eur J Clin Invest. 1999;29:404–412.
    1. Edwards CA, Brown S, Baxter AJ, et al. Effect of bile acids on anorectal function in man. Gut. 1989;30:383–386.
    1. Bampton PA, Dinning PG, Kennedy ML, et al. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol Gastrointest Liver Physiol. 2002;282:G443–G449.
    1. Mitchell WD, Findlay JM, Prescott RJ, et al. Bile acids in the diarrhoea of ileal resection. Gut. 1973;14:348–353.
    1. Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol. 2004;2:796–805.
    1. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138:886–895.
    1. Locke GR, III, Pemberton JH, Phillips SF. American gastroenterological association medical position statement: guidelines on constipation. Gastroenterology. 2000;119:1761–1766.
    1. Spiller RC, Thompson WG. Bowel disorders. Am J Gastroenterol. 2010;105:775–785.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren